Lower Prices, Bigger Market: The Next Phase of GLP-1 Drugs
Cheaper obesity medicines could unlock broader demand, while supply-chain bottlenecks and premium-drug innovation may also shape how the market evolves. Our analysts Terence Flynn and Thibault Boutherin break down the investor implications. Read more insights from Morgan Stanley. ----- Transcript ----- Terence Flynn:…
We score an episode from what we can actually measure — its reach and engagement, what listeners say about it, and what it covers. We don't have those signals for this one yet, so it doesn't get a number.
Buzzmeter says it's buzzing across platforms — the Hive Vote says whether the people who actually listened liked it.
Rate this episode
Add your vote to the Hive — listeners rate every episode after they finish.
- No reviews yet — be the first.
Similar episodes from other shows
More like Thoughts on the Market →
Semaglutide Goes Generic: Big Pharma’s Moat Breaks
The State of Weight-Loss Drugs
India commoditised Novo's blockbuster obesity drug. Novo's not flinching
Here's How the New Weight Loss Drugs Could Change Everything
One great episode in your inbox, daily — free.
One email a day, unsubscribe anytime. No spam, ever.